ReviewFrontiers in oncology2019
Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression.British journal of cancer · 2026Article
- Article
- Instance-based transfer learning enables cross-cohort early detection of colorectal cancer.NPJ biofilms and microbiomes · 2026Article
- Construction of a Mitochondria-Related Gene Diagnostic Model Based on Integrated Multiomics Data and Functional Validation of ANK2 as a Key Regulator in Colorectal Cancer.International journal of genomics · 2026Article
- Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment.Cancer cell international · 2025Review
- Aptamer-Based Strategies for Colorectal Cancer Detection: Emerging Technologies and Future Directions.Biosensors · 2025Review
- New Frontiers of Biomarkers in Metastatic Colorectal Cancer: Potential and Critical Issues.International journal of molecular sciences · 2025Review
- Recent Advances in SAW Sensors for Detection of Cancer Biomarkers.Biosensors · 2025Review
- The HOX Gene Family's Role as Prognostic and Diagnostic Biomarkers in Hematological and Solid Tumors.Cancers · 2025Review
- Current Trends in the Biomarker's Discovery for the Treatment and Management of Colorectal Cancer: A Comprehensive Review.Current medicinal chemistry · 2025Review
- Identification of miR-20a as a Diagnostic and Prognostic Biomarker in Colorectal Cancer: MicroRNA Sequencing and Machine Learning Analysis.MicroRNA (Shariqah, United Arab Emirates) · 2025Article
- Diagnosis and Management of Colorectal Cancer in the Gulf Area: Current Practice and Future Suggestions from Expert Opinions.OncoTargets and therapy · 2025Review
- A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma.SAGE open medicine · 2025Review
- Benchmarking and optimizing microbiome-based bioinformatics workflow for non-invasive detection of intestinal tumors.Microbiome research reports · 2025Article
- Marine-Derived Compound Targeting mTOR and FGFR-2: A Promising Strategy for Breast, Lung, and Colorectal Cancer Therapy.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.Nature reviews. Clinical oncology · 2024Review
- TYK2 Protein Expression and Its Potential as a Tissue-Based Biomarker for the Diagnosis of Colorectal Cancer.Cancers · 2024Article
- Screening differentially expressed proteins to distinguish thymoma (B1 and B3) from thymic cysts based on tandem mass tag (TMT) technology.Journal of cardiothoracic surgery · 2024Article
- Some Glycoproteins Expressed on the Surface of Immune Cells and Cytokine Plasma Levels Can Be Used as Potential Biomarkers in Patients with Colorectal Cancer.Biomolecules · 2024Article
- The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer.International journal of molecular sciences · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is one of the most common cancers in the world, and it is one of the leading causes of cancer-related death. Despite recent progress in the development of screening programs and in the management of patients with colorectal cancer, there are still many gaps to fill, ranging from the prevention and early diagnosis to the determination of prognosis factors and treatment of metastatic disease, to establish a personalized approach. The genetic profile approach has been increasingly used in the decision-making process, especially in the choice of targeted therapies and in the prediction of drug response, but there are still few validated biomarkers of colorectal cancer for clinical practice. The discovery of non-invasive, sensitive, and specific biomarkers is an urgent need, and translational proteomics play a key role in this process, as they enable better comprehension of colorectal carcinogenesis, identification of potential markers, and subsequent validation. This review provides an overview of recent advances in the search for colorectal cancer biomarkers through proteomics studies according to biomarker function and clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.